



Topics in  
**Anti-Cancer  
Research**

**Editor:**  
**Atta-ur-Rahman, *FRS***

**Bentham Books**

**Patents Book Series**  
**“Topics in Anti-Cancer  
Research”**

*(Volume 9)*

**Edited by**  
**Atta-ur-Rahman, *FRS***  
*Kings College,*  
*University of Cambridge,*  
*Cambridge,*  
*UK*

## **Topics in Anti-Cancer Research**

*Volume # 9*

Editor: Atta-ur-Rahman, *FRS*

ISSN (Online): 2213-3585

ISSN (Print): 2468-5860

ISBN (Online): ; 9: /; : 3/36/9884/6

ISBN (Print): ; 9: /; : 3/36/9882/2

ISBN (Paperback): 978-981-14-7661-7

© 2020, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

PREFACE .....	i
LIST OF CONTRIBUTORS .....	ii
<b>CHAPTER 1 RECENT PATENTS ON EXOSOME-DERIVED THERAPEUTIC AGENTS. ....</b>	<b>1</b>
<i>Oğuzhan Karaosmanoğlu</i>	
<b>INTRODUCTION .....</b>	<b>2</b>
<b>EXOSOMES AS VACCINE COMPONENTS .....</b>	<b>3</b>
<b>EXOSOMES AS IMMUNE SUPPRESSORS .....</b>	<b>5</b>
<b>EXOSOMES AS DRUG DELIVERY VEHICLES .....</b>	<b>7</b>
<b>EXOSOMES AS MEDIATORS OF TISSUE REGENERATION .....</b>	<b>9</b>
<b>EXOSOMES AS THERAPEUTIC MOLECULES FOR CANCER TREATMENT .....</b>	<b>12</b>
<b>CURRENT &amp; FUTURE DEVELOPMENTS .....</b>	<b>17</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>18</b>
<b>CONFLICT OF INTEREST .....</b>	<b>18</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>18</b>
<b>REFERENCES .....</b>	<b>18</b>
<b>CHAPTER 2 SERRATED LESIONS OF THE COLON AND RECTUM: AN OVERVIEW OF PATHOLOGY AND EMPHASIS ON A NEW CLASSIFICATION .....</b>	<b>29</b>
<i>Ali Koyuncuer</i>	
<b>INTRODUCTION .....</b>	<b>30</b>
<b>CLASSIFICATION AND TERMINOLOGY .....</b>	<b>30</b>
<b>LOCALIZATION .....</b>	<b>31</b>
<b>CLINICAL, ENDOSCOPIC FEATURES AND RISK FACTORS FOR SERRATED POLYPS OR LESIONS OF THE COLONRECTUM .....</b>	<b>31</b>
<b>PATHOLOGIC FEATURES OF SERRATED LESIONS OR POLYPS .....</b>	<b>32</b>
Hyperplastic Polyp .....	32
Sessile Serrated Lesion .....	34
Traditional Serrated Adenoma .....	37
Unclassified Serrated Adenoma .....	38
<b>DYSPLASIA AND RISK OF CARCINOMA .....</b>	<b>39</b>
<b>MOLECULAR FEATURES .....</b>	<b>40</b>
<b>SURVEILLANCE GUIDELINES FOR CASES WITH SERRATED LESIONS .....</b>	<b>41</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>42</b>
<b>CONFLICT OF INTEREST .....</b>	<b>42</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>42</b>
<b>LIST OF ABBREVIATIONS .....</b>	<b>42</b>
<b>REFERENCES .....</b>	<b>42</b>
<b>CHAPTER 3 INTRODUCING THE 188W/188RE AND 144CE/144PR PLAQUES FOR EYE CANCERS BRACHY THERAPY .....</b>	<b>46</b>
<i>Mohammad Reza Rezaei and Fatemeh Hassanzadeh</i>	
<b>INTRODUCTION .....</b>	<b>47</b>
<b>ENUCLEATION .....</b>	<b>48</b>
ENDORESECTION .....	49
<b>LASER PHOTOCOAGULATION TREATMENT (OPTICAL LASER) .....</b>	<b>49</b>
<b>TRANSPUPILLARY THERMOTHERAPY .....</b>	<b>49</b>
<b>RADIOTHERAPY .....</b>	<b>50</b>
<b>TYPES OF RADIOTHERAPY .....</b>	<b>50</b>
Proton Beam Therapy .....	50

Stereotactic Radiosurgery .....	51
Brachytherapy Treatment .....	51
Brachytherapy .....	51
Different Categories of Brachytherapy .....	52
Advantages of Brachytherapy .....	53
Plaque-Based Brachytherapy .....	53
<b>METHODS AND MATERIALS .....</b>	<b>55</b>
Reactor Production Method .....	55
188W / 188Re Production Method .....	57
144Ce / 144Pr Production Method .....	57
<b>DESIGN AND SIMULATION OF 188W AND 144CE EYE PLAQUES .....</b>	<b>58</b>
<b>PRODUCTION OF 188W / 188RE PLAQUE .....</b>	<b>60</b>
2D Dose Distribution and PDD of 188W/188Re Plaque in Eye and Tumor .....	61
<b>PRODUCTION OF 144CE / 144PR PLAQUE .....</b>	<b>64</b>
2D Dose Distribution and PDD of 144Ce/144Pr Plaque in Eye and Tumor .....	66
<b>CONCLUSION .....</b>	<b>67</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>69</b>
<b>CONFLICT OF INTEREST .....</b>	<b>69</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>69</b>
<b>REFERENCES .....</b>	<b>69</b>
<b>CHAPTER 4 SHcA FAMILY OF ADAPTOR PROTEINS: DUAL ROLE IN CELL GROWTH .....</b>	<b>74</b>
<i>Hilal Ahmad Mir, Roshia Ali and Firdous A. Khanday</i>	
<b>INTRODUCTION .....</b>	<b>74</b>
ShcA Expression and Localization .....	75
Modular Domains of ShcA .....	76
<i>ShcA-PTB Domain .....</i>	<i>76</i>
<i>ShcA-CH1 Domain .....</i>	<i>77</i>
<i>ShcA-SH2 Domain .....</i>	<i>77</i>
<i>ShcA-CH2 Domain .....</i>	<i>78</i>
Cytochrome C Binding Domain .....	78
ShcA in Cell Signaling .....	80
Role of ShcA Proteins in Cell Proliferation and Differentiation .....	81
Role of ShcA Proteins in Metastasis .....	82
Role of ShcA Proteins in Angiogenesis .....	84
Role of P66Shc in Oxidative Stress .....	84
<b>SHcA PROTEINS AS KEY REGULATORS OF CANCER PROGRESSION .....</b>	<b>85</b>
ShcA in Breast Cancer .....	85
ShcA in Ovarian Cancer .....	86
ShcA in Esophageal Cancer .....	86
ShcA in Prostate Cancer .....	86
ShcA in Chronic Lymphocytic Leukemia .....	86
ShcA in other Cancers .....	87
Role of ShcA in Cancer Cell Metabolism .....	87
<b>CONCLUSION AND PERSPECTIVES .....</b>	<b>88</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>88</b>
<b>CONFLICT OF INTEREST .....</b>	<b>88</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>88</b>
<b>REFERENCES .....</b>	<b>88</b>
<b>CHAPTER 5 MELATONIN AS AN ANTI-CANCER AGENT .....</b>	<b>97</b>
<i>Khulood M. Al-Khater</i>	

<b>INTRODUCTION</b> .....	97
The History of the Anti-Cancer Effect of Melatonin .....	99
Melatonin Structure, Synthesis, and Function .....	100
Melatonin Receptors .....	101
<b>ROLE OF MELATONIN IN CANCER</b> .....	102
Molecular Mechanisms .....	102
<i>Anti-oxidant Activity</i> .....	103
<i>Anti-estrogenic Effect</i> .....	103
<i>Enhance Apoptosis</i> .....	104
<i>Anti-proliferative</i> .....	104
<i>Anti-inflammatory</i> .....	104
<i>Anti-angiogenesis</i> .....	105
Examples of Cancer Types .....	106
<i>Lung Cancer</i> .....	106
<i>In vitro Studies</i> .....	106
<i>In vivo Studies</i> .....	109
<i>Clinical Trials and Human Experiments</i> .....	110
<i>Breast Cancer</i> .....	110
<i>In vitro Studies</i> .....	112
<i>In vivo Studies</i> .....	113
<i>Clinical Trials</i> .....	117
<i>Prostate Cancer</i> .....	117
<i>In vitro Studies</i> .....	119
<i>In vivo Studies</i> .....	121
<i>Clinical Trials and Human Experiments</i> .....	122
<i>Colorectal Cancer</i> .....	123
<i>Melatonin in the Gut</i> .....	123
<i>In vitro Studies</i> .....	127
<i>In vivo Studies</i> .....	129
<i>Clinical Trials and Human Experiments</i> .....	130
<i>Ovarian Cancer</i> .....	130
<i>In vitro Studies</i> .....	132
<i>In vivo Studies</i> .....	133
<b>CONCLUDING REMARKS AND FUTURE PERSPECTIVE</b> .....	135
<b>CONSENT FOR PUBLICATION</b> .....	136
<b>CONFLICT OF INTEREST</b> .....	136
<b>ACKNOWLEDGEMENTS</b> .....	136
<b>REFERENCES</b> .....	136

**CHAPTER 6 HORMONES MANAGEMENT AS ANTICANCER TREATMENT AND PROTECTION: FUNCTIONS AND MECHANISM OF ACTION** ..... 155

*Meneerah Abdulrahman Aljafary, Sarah M. Asiri, Fadwa M. Alkhulaifi, Firdos Alam*

*Khan and Ebtesam Abdullah Al-Suhaimi*

<b>GENERAL INTRODUCTION</b> .....	156
Sex Hormones in Anti-Cancer Management .....	156
Gender is a Critical Factor in Cancer and Treatment .....	158
Cellular Mechanism of Hormones Action on Cancer Cells .....	159
Proliferative or Apoptotic Effects of Hormones .....	161
Cardiac Hormones as Anti-Cancer Therapy .....	162
Mechanism of Suppressing the Action of Cardiac Hormones on Cancer cells .....	164
Oxytocin Hormones as Anti-Cancer Agent .....	168



Oxytocinergic System in Neoplastic Cells .....	168
Oxytocin and Breast Cancer .....	169
Oxytocin and Brain Cancer .....	169
Oxytocin And Ovarian Cancer .....	170
Oxytocin and Lung Cancer .....	170
Oxytocin and Endometrial Cancer .....	170
Oxytocin and Prostate Cancer .....	171
Impact of Hormones on Cancer Therapy and Their Implications on Stem Cells Functionality	171
Hormone Therapy in Breast and Thyroid Cancers and Implication of Cancer Stem Cells ....	172
Resistance to Hormone Therapy and the Role of Cancer Stem Cells .....	173
The Management of Endogenous Hormones as Promising Therapeutic Candidates for	
Treating Cancers .....	175
Endogenous Hormones and Cancer .....	175
Role of Thyroid Hormones in Breast Cancer .....	176
Hormonal Variations and Cancers .....	177
Side Effects of Hormone Therapy .....	177
Future Perspectives .....	178
Current Challenges of Hormones Therapy .....	178
<b>CONSENT FOR PUBLICATION</b> .....	179
<b>CONFLICT OF INTEREST</b> .....	179
<b>ACKNOWLEDGEMENTS</b> .....	179
<b>REFERENCES</b> .....	179
<b>SUBJECT INDEX</b> .....	193

## PREFACE

The ninth volume of **Topics in Anti-Cancer Research** covers new developments in the field of cancer. It comprises six comprehensive chapters which are exciting contributions in frontier areas of anti-cancer research.

Karaosmanoğlu presents a discussion on recent patents on exosome-derived therapeutic agents in the first chapter of the volume. The chapter by Koyuncuer deals with serrated lesions of the colon and rectum; he discusses serrated polyps, nomenclature, the particularly associated risk of cancer, terminology and classifications, molecular features and colonoscopic follow-up in this chapter.

Rezaei *et al.* have presented new information on the development of radioactive materials for brachytherapy plaques and selected  $^{188}\text{W}/^{188}\text{Re}$  and  $^{144}\text{Ce}/^{144}\text{Pr}$  plaques for eye cancers brachytherapy.

In the next chapter of the book Mir *et al.* focus on the structure of ShcA proteins and their role in promoting metastasis and progression of various cancers. Understanding the role of ShcA proteins may provide new tools for therapeutic interventions in cancer therapy. Aljafary *et al.* discuss the cellular and molecular role of different types of hormones in treating various kinds of cancers. Other topics related to their impact on stem cell functionality and cancer management are also presented.

Al-Khater, in last chapter of the book, presents an account of the anti-cancer effects of melatonin, focusing on mechanisms of action. Cancers of the lung, prostate, breast, and colon, as well as ovarian cancer are discussed in this context.

I am thankful to the authors for their excellent contributions and to the reviewers for their in-depth comprehensive comments for the improvement of chapters. I am also grateful to Mr. Mahmood Alam (Director Publications), Mr. Obaid Sadiq (Incharge Books Department), Ms. Asma Ahmed (Senior Manager Publications) and other colleagues for their support and assistance in the finalization of this volume.

**Atta-ur-Rahman, FRS**

Kings College  
University of Cambridge  
Cambridge  
UK

## List of Contributors

- Ali Roshia** Department of Biochemistry, University of Kashmir, Srinagar, Jammu and Kashmir 190006
- Al-Khater Khulood M.** Department of Anatomy, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia  
Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- Aljafary Meneerah Abdulrahman** Department of Biology, College of Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- Asiri Sarah M.** Department of Biophysics, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- Alkhulaifi Fadwa M.** Department of Biology, College of Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- Al-Suhaimi Ebtessam Abdullah** Department of Biology, College of Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia  
Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- Hassanzadeh Fatemeh** Department of Nuclear Engineering, Faculty of Sciences and Modern Technologies, Graduate University of Advanced Technology, Kerman, Iran
- Khanday Firdous A.** Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir 190006
- Khan Firdos Alam** Department of Stem Cell Biology, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- Karaosmanoğlu Oğuzhan** Karamanoğlu Mehmetbey University, Kamil Özdağ Faculty of Science, Department of Biology, 70200, Karaman, Turkey
- Koyuncuer Ali** Department of Pathology, Marmara University, Pendik Training and Research Hospital, Istanbul, Turkey
- Mir Hilal Ahmad** Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir 190006
- Rezaei Mohammad Reza** Department of Nuclear Engineering, Faculty of Sciences and Modern Technologies, Graduate University of Advanced Technology, Kerman, Iran

**CHAPTER 1****Recent Patents on Exosome-Derived Therapeutic Agents****Oğuzhan Karaosmanoğlu\****Karamanoğlu Mehmetbey University, Kamil Özdağ Faculty of Science, Department of Biology, 70200, Karaman, Turkey*

**Abstract:** Exosomes are extracellular vesicles that are 30-150 nm in diameter. Exosomes have recently emerged as critical mediators of cell-cell communication by the transfer of DNA, RNA, and protein structured macromolecules between cells and tissues. With the advantage of the distant endocrine signalling, cancer cells use exosomes to suppress the immune system, next contribute to the formation of pre-metastatic niches and angiogenesis. On the other hand, researchers have been benefited from the immunosuppressive, natural carrier, and tissue regenerating roles of exosomes and disclosed patents that are claiming the utilities of exosomes for treating chronic inflammation, autoimmunity related diseases, targeted drug delivery vehicles, and tissue regenerating agents. Moreover, the use of exosomes as vaccine components to prevent cancer, therapeutic molecules for cancer treatment, and the host of biomarkers for the diagnosis and prognosis of cancer are among the issues that are protected by recent patents. The most inspiring one among them could be the incorporation of a therapeutic siRNA that is complementary to oncogenic KRAS<sup>G12D</sup> into CD47<sup>+</sup> exosomes for the treatment of pancreatic cancer. The other one could be the demonstration of the utility of exosomes secreted from dendritic as a cancer vaccine component in phase II clinical trial. It is clear that we have started to understand the fundamentals of exosomes. However, more studies are needed to develop exosome-based cancer vaccines, drug delivery vehicles, immune-stimulating agents that evoke immune cells to kill the cancer cells, and diagnostic and prognostic markers for monitoring cancer in the next years.

**Keywords:** Cancer Vaccines, Chemoresistance, Cancer Diagnosis, Drug Delivery Vehicles, Dexosomes, Exosomes, Genetically Engineered Exosomes, Intercellular Communication, Immune Stimulation, Immune Supp-ression, Immune Tolerance, Multivesicular Bodies, MiRNA, Nucleic Acid Delivery, Pre-metastatic Niche, SiRNA, ShRNA, Tissue Regeneration, Tumour Microenvironment, Viruses.

\* Corresponding author **Oğuzhan Karaosmanoğlu**: Department of Biology, Karamanoğlu Mehmetbey University Turkey; E-mail: karaosmanoglu@kmu.edu.tr

## INTRODUCTION

Extracellular secretory vesicles that are released from various cells can be termed as apoptotic bodies, argosomes, archeosomes, epididimosomes, dexosomes, exosomes, exosome-like vesicles, microvesicles, oncosomes, and promininosomes but mainly divided into three categories that are apoptotic bodies, microvesicles, and exosomes. Differential centrifugation is used to distinguish the subtypes of secretory vesicles. While microvesicles that are of the 200-1000 nm diameter can be precipitated at  $10,000\text{-}20,000 \times g$ , exosomes that are of the 30-150 nm diameter can be precipitated at  $100,000 \times g$  [1]. Besides, exosomes are secreted by the fusion of multivesicular bodies (MVBs) with the plasma membrane [2]. However, microvesicles are released by direct budding of the plasma membrane to outward extracellular milieu [3]. The process of exosome secretion was related to waste disposal mechanism until a study suggesting the exosomes as mediators of intercellular communications in cancer in the 2000s [4]. Upon this initial study, it was demonstrated that exosomes are implicated in both physiological and pathological conditions. In physiology, exosomes involve in coagulation, inflammation, cellular homeostasis [5], immune surveillance [6], fetal survival in pregnancy [7], and neuroprotection [8]. Exosomes contribute to pathological progression of autoimmune diseases [9], cardiovascular diseases [10], neurodegenerative diseases [11], and metastasis [12 - 14]. Beyond this, exosomes are considered as a source of biomarkers that is useful for both diagnostic and prognostic purposes from cancer [15] to Alzheimer [16] with the ability of simply accessible from various body fluids.

Exosomes are produced continuously by nearly all types of cells in the human body [17]. Exosomes can specifically bind to the recipient cells through adhesion molecules like integrin and tetraspanin web complexes [18] then uptaken by the recipient cells with the endocytic pathways such as caveolin-mediated endocytosis, clathrin-mediated endocytosis, lipid raft-mediated endocytosis, macropinocytosis, and phagocytosis [19]. Upon the uptaken, exosomes release the macromolecular contents including, DNA (single-stranded DNA, double-stranded DNA, mtDNA), RNA (mRNA, miRNA, lncRNA and other RNAs), proteins (adhesion molecules (integrins), cell skeleton proteins (actin, tubulin), enzymes, heat shock proteins (Hsp70, Hsp90), receptors (MHC-II, MHC-I, CD86), tetraspanin proteins (CD9, CD63, CD81), and vesicle traffic proteins (Anneksin, TSG01, Alix)) and lipids (ceramide, cholesterol, and sphingolipids) to the cytoplasm of the recipient cells [20 - 22]. Then these molecules modulate recipient cell function and gene expression. With these modulatory effects in the recipient cell, the utilities of exosomes for discovering new treatment methods for cancer have been growing exponentially.

In this chapter, more than thirty of recent patents protecting the use of exosomes as vaccine components, immune suppressors, drug delivery vehicles, mediators of tissue regeneration, and therapeutic molecules for cancer treatment are discussed.

## EXOSOMES AS VACCINE COMPONENTS

With the benefits of circulating in various body fluids and reaching to the distal organs, exosomes can improve the distribution of antigens through the whole body. In addition, exosomes provide stable conditions for maintaining protein structure of the vaccine. Moreover, since exosomes express the adhesion molecules on their surface, the binding and uptake of exosomes by antigen-presenting cells are increased [23]. Therefore, exosomes are newly emerging alternative tools for developing new vaccines.

Exosome biology resembles retroviruses in many details. Both exosomes and retroviruses are about 150 nm in diameter [24]. Both are coated with a lipid membrane, carry genetic material, originate from endosomal pathways, bind to the plasma membranes of recipient cells, uptaken by common mechanisms, and initiate specific reactions by their macromolecular contents in the recipient cells [25]. Moreover, the spread of viral infections to the new cells is facilitated by exosomes. For example, in hepatitis C infected patients, exosomes released from infected cells can transmit infections to new target cells [26]. Thereby exosomes hide viral particles and mediate new infections, like a Trojan horse, by avoiding immune recognition. On the other hand, researchers are making efforts to produce DNA vaccines by using the ability of exosomes to transport viral particles. In a recent patent, the inventors discovered that an exosome expressing a fusion antigen protein has excellent cytotoxic T-cell inducibility [27]. After this patent coverage, there is an attempt to produce vaccines by using DNA vectors that are expressing viral proteins on the exosomes [28]. This approach is found useful for the development of vaccines against viral diseases such as Ebola Virus VP24, VP40, and NP, Influenza Virus NP, Crimean-Congo Hemorrhagic Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3 [29]. However, this exosome-based vaccination procedure is not examined with clinical trials.

There is accumulating data for the utility of exosome-based vaccines in the management of non-viral infectious diseases caused by pathogenic microorganisms such as *Corynebacterium diphtheriae* [30], *Eimeria tenella* [31], *Leishmania major* [32], *Mycobacteria tuberculosis* [33], and *Streptococcus pneumoniae* [34]. These vaccination procedures are not examined with clinical trials. Therefore, the clinical utility of these vaccines is remained unclear for now.

When it comes to cancer, one might suggest that if I educate immune cells with cancer cell-derived exosomes, then these exosomes would mediate the elevated

---

**CHAPTER 2**

---

**Serrated Lesions of the Colon and Rectum: An Overview of Pathology and Emphasis on a New Classification****Ali Koyuncuer\****Department of Pathology, Marmara University, Pendik Training and Research Hospital, Istanbul, Turkey*

**Abstract:** The most common malignancy in the gastrointestinal tract is colorectal carcinomas (CRC), which is the second most common cancer in women and the third most in men worldwide. Adenomas are the most frequently observed precursor lesions for CRC. Two basic pathways have been defined for CRCs: the classical adenoma-carcinoma sequence and serrated pathway developing from sessile serrated lesions or adenomas. In the previously reported literature, there is no potential for malignancy, but now the serrated neoplasia pathway is observed in approximately 30% of all CRCs. In large colonoscopic series studies, the prevalence of serrated polyp is approximately 20%. Colorectal serrated lesions are characterized by sawtooth or stellate morphological features of the epithelium. For sessile serrated lesion (SSL) definition, according to the World Health Organization (WHO) Classification of Tumors of the Digestive System 2019, the presence of at least 1 unequivocal distorted crypt is considered sufficient for diagnosis. There is major variability in the morphology of colorectal serrated lesions or polyps, and as a consequence, a number of pathological subtypes have been described and 3 significant types have been defined; hyperplastic polyp (HP), sessile serrated lesion (SSL), and traditional serrated adenoma (TSA). HP is the most common lesion among all serrated polyps, and the potential for colorectal cancer development is very low. Improving the detection of SSLs reduces both the incidence and mortality of CRCs and reduces the risk of developing cancer of interval cancers. In this article, we will discuss serrated polyps, nomenclature, the particularly associated risk of cancer, terminology and classifications, molecular features and colonoscopic follow-up with the current designation.

**Keywords:** Cancer, Colonoscopy, Colorectal, Distorted, Dysplasia, Epidemiology, Gastrointestinal Tract, Histopathology, Hyperplastic, Immunohistochemistry, Localization, Macroscopic Appearance, Molecular, Polyps, Prognosis, Sessile, Serrated, Traditional, Unequivocal, WHO.

---

\* **Corresponding author Ali Koyuncuer:** Department of Pathology, Marmara University, Pendik Training and Research Hospital, Istanbul, Turkey; Tel: 0506 3819 352, (0216) 6570 606; Fax: (0216) 625 45 45; E-mail: alikoyuncuer@hotmail.com

## **INTRODUCTION**

Adenocarcinoma is the most common malignant epithelial tumors of the colon, rectum. In 2018, 1 849 518 new cases (about 10.2% of all cancers) were reported worldwide, which is the second most common cancer in women and the third in men [1, 2]. In 2018, 880 792 deaths (approximately 9.2% of deaths reported from all cancers) were reported due to colorectal cancer. In Europe, the incidence of colorectal cancer is very high in some countries, while in Asia and some Africa regions, the incidence is very low [2]. Incidence and mortality are 25% less in women than in men. Especially in developing countries, it is estimated that colorectal cancers will reach new cases between 2-5 million years old in 2035. An important reason for this is thought to be the result of the increase or development of colonoscopy screening [3]. Recent studies have been published over the past twenty years regarding serrated polyps or lesions, and evidence on clearly, defined classifications are available. Detection of precursor lesions of colorectal carcinomas is one of the main targets of colonoscopy screening and surveillance programs today [4]. It was known that serrated lesions had no potential for malignancy for a long time. However, an increasing number of molecular studies have yielded clear conclusions about colorectal carcinoma pathogenesis. Almost all CRCs are believed to develop from a precursor adenoma, and many studies have been shown when detecting the classic adenoma-to-carcinoma sequence, while other carcinoma pathways are present [5]. This process, defined as a serrated neoplastic pathway, has been shown to develop colorectal cancer from serrated polyp or adenomas. In the past few decades, all serrated polyps were considered to be hyperplastic, but thanks to new developments, it was shown to have the malignant potential of hyperplastic polyps [6]. The most important reason for insufficient diagnosis of SSL can be related to the fact that clinicians and pathologists lack awareness of these lesions. This demonstrated the importance of pathologists or colonoscopists in recognizing these lesions, especially in colorectal cancer screening programs.

## **CLASSIFICATION AND TERMINOLOGY**

Polyps with different growth, differentiation patterns and combined morphological features, hyperplastic and adenomatous epithelium, were previously defined as a mixed hyperplastic adenomatous polyp. For the first time in 1990, potentially different lesions were evaluated in the category of serrated adenoma by Longacre and Fenoglio-Preiser [7]. Classical criteria of hyperplastic polyps (HPs) include a serrated epithelium on the surface and limited proliferative zone, narrow straight crypts in uniform spaced crypts. Serrated adenomas (SAs)



were defined as dilatation in T and L shaped crypt bases, serration in crypt bases, abnormal proliferation and also in crypt bases determination of goblet or foveolar cells [8]. Today, the WHO-2019 reported that 1 or more unequivocal architecturally distorted serrated crypt would be sufficient for SSL diagnosis. Serrated lesions of the colorectum are subdivided into four categories by WHO-2019 (5<sup>th</sup> edition): Hyperplastic polyp, sessile serrated lesion (SSL, formerly known as sessile serrated adenoma/polyp), traditional serrated adenoma (TSA) and unclassified serrated adenoma. SSL terminology, which is one of the most important changes in the fifth edition, has been defined according to the opinion that not all lesions have a polypoid appearance [4].

## LOCALIZATION

Hyperplastic polyps are more frequently showed in the distal colon and rectum. SSLs predominantly occur in the proximal colon; about 25% are detected distal to the splenic flexure [9]. Approximately 70% of TSAs are detected in the distal colon-rectum or left colon [9, 10].

**Table 1. Classification of colorectal serrated lesions or polyps.**

<b>Histologic Subtypes</b>
Hyperplastic Polyp Microvesicular HPs (MVHPs) Goblet Cell-Rich HPs (GCHPs)
Sessile Serrated Lesion
Sessile Serrated Lesion with Dysplasia Intestinal Dysplasia Serrated Dysplasia
Traditional Serrated Adenoma
Unclassified Serrated Adenoma

## CLINICAL, ENDOSCOPIC FEATURES AND RISK FACTORS FOR SERRATED POLYPS OR LESIONS OF THE COLONRECTUM

HPs are defined as small and innocuous lesions observed in the adult colon. They increase with age, especially one-third of the increase in asymptomatic individuals after age 50. These lesions detected incidentally during colonoscopic examination are generally asymptomatic and associated with smoking, alcohol and obesity. It is sometimes difficult to distinguish from classical adenomas clinically [11]. A diet rich in fats creates risk, and it has been reported that the use of NSAID and aspirin has protective properties [12]. On the other hand, age, female sex, diabetes

## Introducing the $^{188}\text{W}/^{188}\text{Re}$ and $^{144}\text{Ce}/^{144}\text{Pr}$ Plaques for Eye Cancers Brachytherapy

Mohammad Reza Rezaei\* and Fatemeh Hassanzadeh

*Department of Nuclear Engineering, Faculty of Sciences and Modern Technologies, Graduate University of Advanced Technology, Kerman, Iran*

### **Abstract:**

#### **Background:**

Plaque brachytherapy has been introduced as a treatment for ocular melanoma, an intraocular tumor, and is an available alternative to eye enucleation. Brachytherapy is one of the radiotherapy methods, which uses radioactive sources near or on the tumor.

#### **Introduction:**

So far, various plaques have been used to treat eye tumors. The aim of this research is the development of radioactive material for brachytherapy plaques.

#### **Method:**

In order to introduce and produce new brachytherapy plaques, all the isotopes of the periodic table of elements have been identified, and the mother and daughter of elements whose mother had long half-life beta decay and its daughter had a short half-life have been identified and the method of mother production has been examined.

#### **Result:**

After reviewing, two new  $^{188}\text{W} / ^{188}\text{Re}$  and  $^{144}\text{Ce} / ^{144}\text{Pr}$  plaques have been selected for use in brachytherapy.

#### **Conclusion:**

Each of the new plaques has a special advantage in comparison with old plaques. The 2D dose distribution of  $^{188}\text{W}/^{188}\text{Re}$  and  $^{144}\text{Ce} / ^{144}\text{Pr}$  plaques in eye and tumor was obtained and was compared with old plaques.

---

\* Corresponding author **Mohammad Reza Rezaei**: Department of Nuclear Engineering, Faculty of Sciences and Modern Technologies, Graduate University of Advanced Technology, Kerman, Iran; E-mail: mr.rezaie.r@gmail.com

**Keywords:**  $^{188}\text{W}$  /  $^{188}\text{Re}$  Plaque,  $^{144}\text{Ce}$ ,  $^{144}\text{Pr}$  Plaque, Brachytherapy, Beta Radiation, Eye Cancer, Elements, Half Life, MCNPX Code, Melanoma, Reactor, Serum-144, Tumor, Tangsen-188.

## INTRODUCTION

Eye cancer is a rare but debilitating disorder. This cancer can affect the outer and inner parts of the eye. The most common cancers in adults are melanoma and lymphoma, while in children, retinoblastoma may be outside or inside the eye [1]. A large percentage of the cells in this tumor is retinoblasts in terms of retinal tissue [2]. At a stage of evolution, cells prevent division, and they become adult retinal cells. Typically, this process is controlled by normal RB1 genes. Some cells grow out of control and cause cancer. This resemblance prompted Verhoeff to coin the term retinoblastoma, which was adopted by the American Ophthalmological Society in 1926 as a general term for this eye cancer [3]. Retinoblastoma usually occurs in children under 5 years of age [2]. In some patients, the tumor may start in one or both eyes. If retinoblastoma is not detected in time, it may involve a significant portion of the eyeball [2]. Melanoma is a relatively rare tumor that results from melanocytes in various anatomical sites, including the skin, mucous membranes, eye area, and rarely from unknown primary sites. Melanoma are special cells that makeup melanin, and because of its origin in melanocytes, it is called melanoma. Most UMs are returned depending on where they are located; *i.e.*, UMs are often referred to by their location; *i.e.*, the origin of iris melanoma is elsewhere, but it attacks the iris. Although iris melanoma is derived from uveal, it is more common with cutaneous melanoma [4, 5]. Mutations in the BAP1 gene are strongly associated with two options: metastatic spread and patient survival [6]. The incidence of ocular tumors varies according to the age and race of the patient. UM affects people with fair skin, light eye color, and European descent [2, 7 - 9]. A New York City study found that the annual incidence of UM in black patients is 0.31 per million [2]. UM's propensity for lightly pigmented persons and the posterior part of the uveal tract suggests that UV light may play a role in pathogenesis, but studies are inconclusive [10, 11]. Retinoblastoma is the most common cancer worldwide, and UM is the most common cancer in Europe and the United States [4]. From 84836 of the National Cancer Database between 1985 and 1994, the percentage of melanoma in the skin, eyes, mucosa, and primary unknown was 9%, 5%, 1%, and 2%, respectively. Melanoma of the ocular structures accounts for approximately 5% of all melanomas. Most (95%) are UV allele melanomas. Men have a higher rate of melanoma than women. The causes of melanoma are ambiguous. However, several host and environmental factors have been studied. Clinical, epidemiological, physiological, and genetic data suggest that ultraviolet radiation an important parameter in UVL melanoma development. Melanoma is not an

inherited disease. The lesions may be associated with pigmented spots in the iris, cataracts, blurred vision, blinking, gradual weakness in the visual field, or severe eye pain. The consequences of vascular melanoma can be served and dangerous. Such as the risk of metastasis and the development of a malignant secondary tumor in areas far from the main tumor, which usually develops in the liver, is the leading cause of death among metastatic ocular melanoma patients [12]. The most common sign of melanoma inside the eye is vision loss, and another symptom is pupillary whiteness [2, 8, 9]; worsening vision over weeks to months; blurred vision or sudden loss of vision; floaters or flashes of light; loss of part of the visual field; a growing dark spot on the iris; change in pupil size or shape; bulging of the eye; and change in how the eye moves [7, 8, 13]. Oncogenic mutations in GNAQ or GNA11 (genes encoding for widely expressed G protein alpha subunits), which are observed in >80% of primary UMs, activate signaling pathways, including the mitogen-activated protein kinase pathway. Most intraocular melanoma originates in the iris and is easily seen. A small percentage of these spread to other parts of the body. About 50% of UMs harbor mutations in the GNAQ or GNA11 genes that encode G protein-coupled receptors in the RAF/MEK/ERK pathway, also found in benign lesions. Congenital ocular melanocytosis GNAQ mutations are thought to be an early or initiating event in the pathogenesis of UM [2, 14 - 16]. The National Cancer Institute's Surveillance, Epidemiology, and end Results data on about 1,500 patients diagnosed with eye melanoma between 1988 and 2001 show that, overall, about 3 out of 4 people with eye melanoma survive for at least 5 years [17]. Survival rates are higher in the early stages of diagnosis, but the exact survival rate of ocular melanoma is difficult because it is rare cancer [9, 17, 18]. When the cancer is confined to the eye, the 5-year relative survival rate is about 80% [17]. For people with eye melanomas that have spread to distant parts of the body, the 5-year relative survival rate is about 15%. If there is spread outside the eye, a stage is assigned [18]. About half of patients with melanoma develop metastases between 10 and 15 years later, which is very fatal [2, 9]. Methods of diagnosing melanoma include: indirect ophthalmology, deep eye photography, fluorescent angiography, ultrasound, MRI, CT, complete biopsy [12]. There are several treatments for eye cancer, the most common of which are radiation therapy and eye drainage. Radiation therapy includes external radiotherapy (proton therapy, hadron therapy and gamma knife) and brachytherapy (using radioactive plaque) [19, 20].

## **ENUCLEATION**

Enucleation is used for advanced and large melanoma, which occupies most of the structures inside the eye and has no hope of healing. It is used for those who have developed secondary gradual blindness and involves removing the entire visual

## ShcA Family of Adaptor Proteins: Dual Role in Cell Growth

Hilal Ahmad Mir<sup>1,\*</sup>, Roshia Ali<sup>2</sup> and Firdous A. Khanday<sup>1,\*</sup>

<sup>1</sup> Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir 190006

<sup>2</sup> Department of Biochemistry, University of Kashmir, Srinagar, Jammu and Kashmir 190006

**Abstract:** ShcA proteins are the family of adaptor proteins that mediate biological responses by transducing extracellular signals into intracellular signals. ShcA family consists of three different alternatively spliced or alternative translational initiated isoforms known as p66Shc, p52Shc and p46Shc. The p52 and p46Shc isoforms are usually involved in promoting cell growth, mediating their action by activating mitogen-activated protein kinases (MAPK) and phosphoinositide-3-kinase/Akt signalling pathways. However, the p66Shc isoform acts as a dual player in cell development and is involved in stimulating both cell proliferative and apoptotic pathways. Any deregulation in the expression of ShcA proteins and pathways regulated by ShcA proteins results in the occurrence of different types of cancerous diseases, including breast cancer, thyroid cancer, prostate cancer and lung cancer. Aberrations in the expression of ShcA proteins have been demonstrated to promote key elements of cancer progression, including cell migration, cell proliferation, metabolic reprogramming, angiogenesis and tumorigenesis. Based on all these studies, the present chapter focuses on the structure of ShcA proteins and their role in promoting metastasis and progression of various cancers. Understanding the role of ShcA proteins may provide new tools for therapeutic interventions in dreadful cancer disease.

**Keywords:** Adaptor proteins, Apoptosis, Aging, Cell proliferation, Cell differentiation, Cell signalling, Cell survival, Metabolism, Modular domains, Neoplasms, Oxidative stress, Reactive oxygen species, Vascularization.

### INTRODUCTION

ShcA proteins are one of the subtypes of the Shc family of adapter proteins, which

\* Corresponding authors Hilal Ahmad Mir & Firdous Ahmad Khanday: Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir, 190006, India; Tel: 7006 6554 96 / 9906 9542 50, 7006 2876 45 / 9906 4622 06; E-mails: hilalmir1613@gmail.com & khandayf@kashmiruniversity.ac.in

act as transducers of extracellular signals to intracellular in different signal transduction pathways [1]. ShcA family consists of three different proteins p46, p52 and p66Shc, which arise from the same gene locus [2].

However, different isoforms of ShcA are generated from two mRNAs *via* RNA splicing and alternative translational initiation [3]. The p46shc/p52shc isoforms are formed by the assembly of the non-coding exon 1 with the 3' portion of exon 2 (exon 2a), and with exons 3-13 while the p66shc transcript is formed by the assembly of exons 2-13 [4]. Apart from this, the translation process is also involved in the formation of these three isoforms, while the two shorter isoforms p52/p46Shc use two translational in-frame ATG start codons, the longest p66Shc isoform product formation utilizes three ATGs in-frame start codons [4]. Structurally, all isoforms of the ShcA family have a distinctive modular character, containing phosphotyrosine binding (PTB) domain at N-terminal end, which is linked to C-terminal Src homology 2 (SH2) domain by Collagen homology (CH1) linker domain [5]. A cytochrome C binding domain is also present in p66Shc and P52Shc isoform. Nevertheless, 66kda isoform contains an extra glycine/proline rich fragment linked to N-terminus of PTB domain known as collagen homology (CH2) domain, which makes it the longest and the most different from the other two isoforms. Moreover, p52Shc and p46Sh are ubiquitously expressed while p66Shc displays a constrained pattern of expression [5]. P52/46Shc proteins have been implicated in the regulation of diverse cellular functions like cell survival, cell proliferation, cell-cell adhesion and cell migration, whereas p66Shc is mainly involved in reactive oxygen species (ROS) production, apoptosis, aging and cell metabolism, *etc*. ShcA proteins have also been implicated in the progression of many cancers including colon cancer, pancreatic cancer and breast cancer, *etc* [6 - 8]. The ability of ShcA proteins to activate different signalling pathways and mediate different biological responses is endorsed to its multi-domain organization which enables these proteins to interact with the number of other proteins, thereby regulating different biological processes.

### **ShcA Expression and Localization**

ShcA isoforms are expressed differentially both at the cellular level and tissue level; while the longest isoform p66Shc is specifically expressed in most of the cells except hematopoietic lineage and in tissues including heart, kidney, lungs, liver and spleen, the two shorter isoforms show ubiquitous pattern of cellular and tissue expression [9]. Epigenetic modifications also play a crucial role in the regulation of ShcA expression [10]. Demethylating agents and histone deacetylase inhibitors have been reported to positively regulate p66Shc protein expression in a dose-dependent manner [11]. A class III histone deacetylase enzyme SIRT1 was

observed to bind p66Shc promoter directly and represses its transcription by deacetylating Lys9 in histoneH3. Moreover, the exogenous introduction of SIRT1 in mice showed alleviations in mRNA and protein levels of p66Shc. Similarly, a significant enhancement in p66Shc expression was found in response to low-density lipoproteins induced methylation of p66Shc promoter [12].

Besides variances in expression pattern, ShcA proteins also show differences in their localization pattern. P66Shc is mainly located in the cytoplasm, mitochondria and endoplasmic reticulum [13]. P52Shc is found on membranes of endoplasmic reticulum, while p46Shc is directed to mitochondrial matrix by mitochondrial specific signals [14, 15] (Table 1).

**Table 1. Characterization of ShcA family.**

S. No.	Character	P66Shc	P52Shc	P46Shc
1.	Number of amino acids	583	473	428
2.	Molecular weight	66 kDa	52 kDa	46 kDa
3.	Structural Domains	CH2-CB-PTB-CH1-SH2	CB-PTB-CH1-SH2	PTB-CH1-SH2
4.	Localization	Cytoplasm, mitochondria and endoplasmic reticulum	Endoplasmic reticulum	Mitochondrial matrix
5.	Expression pattern	constrained	ubiquitous	ubiquitous
6.	Functions	Apoptosis, ROS production, Rac1 activation and ageing	Ras regulation, cell survival, cell growth, Cytoskeleton Organization.	Ras regulation, cell proliferation, Cytoskeleton Organization
7.	Occurrence	Vertebrates	Amphibians, nematodes, insects, fishes and mammals	Amphibians, nematodes, yeasts, insects, fishes and mammals

## **Modular Domains of ShcA**

### ***ShcA-PTB Domain***

ShcA phosphotyrosine binding domain (PTB), made of around 195 amino is also known as the phosphotyrosine interaction domain (PID). This domain consists of 3 alpha-helices and 7 beta-sheets [14]. ShcA-PTB domain shares some structural similarity with the pleckstrin homology (PH) domain possessing a  $\beta$ -sandwich

## Melatonin as an Anti-cancer Agent

**Khulood M. Al-Khater\***

*Department of Anatomy, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia*

*Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia*

**Abstract:** Cancer is a disease that causes a huge health burden for communities. Despite the great progress made in diagnostic tools for cancer and the advancement of treatment strategies, cancer is still one of the commonest causes of death in the world. Melatonin, a hormone produced mainly by the pineal gland, possesses an anti-cancer property. The discovery of this effect of melatonin on cancer cells was a breakthrough in the field of cancer research. Several lines of evidence support this property of melatonin, including *in vitro* and *in vivo* studies and clinical trials. This effect of melatonin was examined in various types of cancer, and a consensus has been reached with regard to its oncostatic/anti-cancer effect. Multiple mechanisms have been proposed for this effect of melatonin, among which are the anti-oxidant, anti-inflammatory, anti-estrogen/androgen, anti-angiogenic, and pro-apoptotic actions of melatonin. This chapter presents an account on the anti-cancer effect of melatonin, focusing on mechanisms of action by presenting examples of cancer types, including the most common types of cancer in the world: cancers of the lung, prostate, breast, and colon, as well as ovarian cancer.

**Keywords:** Breast cancer, Cancer, Colorectal cancer, Lung cancer, Melatonin, Oncostatic effect, Pineal gland, Prostate cancer.

### INTRODUCTION

Melatonin is a naturally occurring hormone secreted by various types of tissues in the body, mainly by the pineal gland. The pineal gland is a small endocrine gland that forms part of the diencephalon of the brain. It is attached to the posterior aspect of the third ventricle by a stalk. The pineal gland is a highly vascular structure and has two types of cells: pinealocytes and neuroglial cells. The pinealocytes are the cells that synthesize and secrete melatonin.

---

\* **Corresponding author Khulood M. Al-Khater:** Department of Anatomy, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia; Tel: 00966504903833; E-mail: kalkhater@iau.edu.sa



The secretion of melatonin is regulated by the circadian rhythm of the body, being higher at night [1]. Serum melatonin level during darkness (night-time) is higher than that during daytime. The regulation of melatonin secretion is achieved by input from the circadian pacemaker, the suprachiasmatic nucleus (SCN), one of the hypothalamic nuclei [1, 2]. The SCN receives information about time of the day from the retina through the retino-hypothalamic pathway. The neural connection between the SCN and the pinealocytes of the pineal gland is an indirect one. This connection descends through the reticular formation of the brainstem to reach the sympathetic neurons in the upper thoracic part of the spinal cord. From there, the preganglionic fibers synapse with postganglionic neurons in the superior cervical ganglion, whose axons reach the pinealocytes and make synaptic contact with them. Noradrenaline (norepinephrine) is the neurotransmitter secreted by the sympathetic fibers to cause the secretion of melatonin from the pinealocytes. This pathway is activated by darkness and deactivated by light. Therefore, melatonin production is primarily under sympathetic control, and other hormones do not play any known role in its control.

Melatonin was first discovered in the late 1950s after the work of Lerner and co-workers, who isolated this hormone from bovine pineal gland [3]. Starting in the 1970s, studies demonstrated that melatonin is also secreted by extra-pineal sites, such as the retina, gastrointestinal tract, skin, thymus, and bone marrow [4, 5]. Moreover, it has recently been reported that melatonin is secreted by any cell with a nucleus [6].

Initially, the role of melatonin was thought to be limited to the control of the circadian rhythm, but further studies have shown that it is implicated in many physiological functions of the body. Now, it is believed that the control of the circadian rhythm is mainly performed by pineal melatonin, whereas extra-pineal melatonin is implicated in the other physiological functions elaborated below [6].

Some scientists argue that melatonin possesses several properties beyond those of classical hormones [7]. This is because it acts like an autocoid (used by the cells of the source, such as the retina), paracoid [used by the cells in the vicinity of the source, such as neural tissue from the cerebrospinal fluid (CSF)], and as a free radical scavenger (anti-oxidant). In addition, the pineal gland, unlike other endocrine glands, lacks storage machinery for melatonin and the regulatory feedback mechanisms known for hormonal function. This is in addition to the fact that melatonin is secreted by extra-pineal sources not recognized as endocrine glands. Food is also a known source of melatonin; thus, it can be regarded as a vitamin [7].

Several basic and clinical studies have reported a beneficial effect of melatonin administration in the treatment of a number of organic or psychological diseases [8, 9]. One of the organic diseases that showed a positive response to melatonin was cancer [10 - 12]. Melatonin has well-documented anti-cancer properties that have attracted the attention of researchers since the last century. It has been found that the cancer inhibition properties of melatonin are present at various levels of cancer development, including the early and late stages [13, 14]. The recent literature in the field of cancer therapy is advocating the use of melatonin as an adjuvant therapy with other treatment modalities [15]. This recommendation is based on the evidence obtained from a few clinical trials that showed improved survival and outcomes among cancer patients treated with melatonin, in addition to chemo- or radiotherapy, as compared to patients who received only traditional therapy [16]. Lissoni's research group was active in addressing the issue of melatonin treatment for cancer patients [10, 11, 17 - 20]. Mills *et al.* [16] conducted a meta-analysis of Lissoni's group studies and found a significant difference between patients who used melatonin as an adjuvant to chemotherapy and patients who used chemotherapy only. Following these studies, more interest has been directed toward melatonin as an anti-cancer agent. Currently, researchers focus on investigating the underlying mechanisms of this anti-cancer effect of melatonin. This chapter highlights the current views on the role of melatonin in the prevention and treatment of cancer.

### **The History of the Anti-Cancer Effect of Melatonin**

The notion that melatonin has an anti-cancer effect is not recent. Rather, it arose around the middle of the last century. More attention was paid to this relationship between melatonin and cancer after the observations of Cohen and co-workers, who presented a hypothesis, in 1978, that referred to a potential relationship between pineal gland dysfunction (for example, pineal calcification) and the increased incidence of breast cancer in women [21]. They suggested an inhibitory effect of melatonin on the production of estrogen; therefore, the reduction of melatonin leads to an increase in estrogen level and, thus, increases the risk of the development of breast cancer. Their study published in 1981 provided evidence for this relationship [22]. In that study, they performed pinealectomies in rats and observed that this procedure stimulated the development of 9,10-dimethyl-1-2-benzanthracene (DMBA)-induced mammary tumors, whereas rats that received melatonin were protected from developing such tumors.

Recent research work has documented this oncostatic effect of melatonin on various types of cancers, including cancer of the breast [23, 24], lung [25], gut [26 - 29], liver [30], pancreas [31], prostate [32], ovary [33], uterus and cervix [34],

## CHAPTER 6

# Hormones Management as Anticancer Treatment and Protection: Functions and Mechanism of Action

Meneerah Abdulrahman Aljafary<sup>1</sup>, Sarah M. Asiri<sup>3</sup>, Fadwa M. Alkhulaifi<sup>1</sup>, Firdos Alam Khan<sup>4,\*</sup> and Ebtesam Abdullah Al-Suhaimi<sup>1,2,\*</sup>

<sup>1</sup> Department of Biology, College of Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

<sup>2</sup> Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

<sup>3</sup> Department of Biophysics, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

<sup>4</sup> Department of Stem Cell Biology, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

**Abstract:** The available therapy for cancers mostly revolves around chemotherapy, radiation, immunotherapy, and surgery, but these treatment modalities are not satisfactorily treating the patients and are associated with various side effects, pain, immune reduction, trauma, and also induce drug resistance in some patients. Besides, these treatments do not treat the disease's origin but eliminate the tumor itself somewhat without confirmation of avoiding its metastasis. Therefore, there is a need to develop a new effective therapy to treat cancer patients successfully. Hormones naturally present in the human body for controlling various biological and physiological functions also possess potential capabilities to treat different types of cancers. Both preclinical and clinical data show that hormones include anticancer abilities, are controlled by hormonal managing. This chapter has discussed the cellular and molecular role of different types of hormones in treating various kinds of cancers and other pertinent topics related to their impact on stem cell functionality and cancer management.

**Keywords:** Anticancer Treatment, Cardiac hormones, Functions, Hormones, Management of endogenous hormones, Mechanism of Action, Oxytocin hormones, Sex hormones, Stem cell functionality.

\* Corresponding authors Ebtesam Abdullah Al-Suhaimi & Firdos Alam Khan: Department of Biology, College of Sciences & Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Post Box No. 1982, Dammam 31441, Saudi Arabia; E-mail: ealsuhaimi@iau.edu.sa and Department of Stem Cell Biology, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Post Box No. 1982, Dammam 31441, Saudi Arabia; E-mail: fakhan@iau.edu.sa

Atta-ur-Rahman (Ed.)

All rights reserved-© 2020 Bentham Science Publishers

## **GENERAL INTRODUCTION**


Cancers pose severe global health challenges, and millions of patients are currently present in different parts of the world. One of the challenges of the different types of cancer is early diagnosis and treatment. The cancers' available therapy mostly revolves around chemotherapy, radiation, immunotherapy, and surgical interventions. Unfortunately, all of these treatments fail to provide a complete cure to patients and come with various side effects; pain and trauma also induce drug resistance in some patients. Therefore, there is a need to develop effective therapy management, which can successfully be investigated and used to treat cancer patients. Hormones usually produced in the human body for regulating various biological and physiological functions also possess potential capabilities to treat different types of cancers. Both preclinical and clinical studies show that hormones possess anti-cancer potential. In the present chapter, we have discussed the roles of different hormones, such as sex hormones, cardiac hormones, and oxytocin hormones, as anti-cancer agents. We have also discussed the topics, such as the impact of hormones on cancer therapy and their implications on stem cell functionality and the management of endogenous hormones as promising therapeutic candidates for treating cancers.

### **Sex Hormones in Anti-Cancer Management**

Cancer causes severe health problems, and it is estimated to be responsible for millions of deaths by 2030. Breast cancer is one of the significant cancers causing many lives due to the lack of proper protection, diagnosis, and treatment availabilities. The role of estrogen receptor-positive [ER+] on breast cancer is a significant target for anticancer therapy as [ER+] represents 75% of all breast cancers. The female estrogen hormones initiate and progress breast malignancy; hence estrogen receptors have been targeted at breast cancer treatment. Estrogen alpha receptors have been targeted by therapies to suppress the estrogen effect [1, 2].

Dehydroepiandrosterone [DHEA] is an inactive steroidal hormone, secreted by the adrenal cortex [zona reticularis] with age-related secretion patterns; it declines 2% per year. DHEA transformed in peripheral target tissues into active sex steroids, responsible for most body functions, involving the endocrine system. Besides, to serve as an indirect precursor to other steroid hormones [estrogen and testosterone], DHEA is used as an anticancer, anti-allergic treatment, and treatments for obesity and cardiovascular problems. DHEA is also known as an anti-aging hormone in dementia and osteoporosis [3]. New approaches focus on preserving the brain as it controls homeostasis's primary role in the body [4]. With age progression, all tissues noticeably observed to decline in physiological

functions and are increasingly susceptible to disease. Sex-steroids are associated with many human diseases, including hormone-dependent tumors. Women with premenopausal show fluctuating estradiol concentrations [E2] and progesterone [P4] levels in their blood circulation. After menopause, blood circulating hormones reduce, but they are still present in high peripheral tissue concentrations. There is a strong link between the amount of circulating hormone levels and female reproductive cancers, including breast cancer; the hormones bind to estrogen receptors [ERs] [ER $\alpha$ , ER $\alpha$ 36, ER $\beta$ ], or progesterone receptors [PRs] activating specific signaling pathways. Endocrine therapy uses after identifying ER or PR positive tumors [5]. The influence of sex hormones on many physiological functions is shown in Fig. (1).



**Fig. (1).** Sex hormones influence many physiological functions: cancer progression, anticancer immunity, and cardiovascular system.

Estrogen is essential for the average growth and development of breast tissues, but high estrogen levels are major risk factors for breast cancer. One mechanism by which estrogen could contribute to breast cancer is through the induction of DNA damage. The estrogen alters the DNA damage response (DDR) and DNA repair by regulating essential effector proteins, including ATM, ATR, CHK1, BRCA1, and p53. There is a possibility that estrogen receptor signaling converges to

SUBJECT INDEX

**A**

Acid 9, 113, 129  
 alpha-glucosidase gene GAA 9  
 ursolic 129  
 valproic 113  
 Acidic phospholipids 77  
 Action 97, 101, 103, 112, 121, 122, 159, 160,  
 164, 166, 167, 168  
 anti-androgenic 121  
 anticancer 160, 166, 167  
 anti-oxidant 101, 103  
 antiproliferative 159, 168  
 anti-tumor 122  
 of cardiac hormones on cancer cells 164  
 melatonin's 112, 122  
 pro-apoptotic 97  
 Activation 6, 82, 85, 101, 103, 104, 112, 116,  
 120, 121, 128, 133, 169, 171  
 induced cell death process 6  
 Activator of transcription 167  
 Activity 6, 7, 8, 15, 17, 57, 58, 60, 61, 64, 78,  
 82, 84, 103, 105, 168  
 anticancer 8, 168  
 antigen processing 15  
 anti-inflammatory 8  
 cytotoxic 6, 7  
 immunosuppressor 6  
 melanoma inhibitory 84  
 metabolic 103  
 suppress anti-cancer 105  
 tissue regenerating 17  
 Adenocarcinoma 16, 17, 30, 40, 86, 106, 121,  
 165  
 esophageal 86  
 human prostate 165  
 mucinous 41  
 ovarian serous 17  
 transgenic 121  
 Adenomas 29, 30, 31, 39, 40  
 classical 31  
 conventional 39, 40  
 Adenyl cyclase 101

Adjuvant 99, 110, 133, 134  
 therapy 99, 110, 134  
 treatment 133  
 Androgen deprivation therapy of prostate  
 cancer 178  
 Anti-cancer effect of melatonin 97, 99, 102,  
 124, 129, 133, 134  
 Anti-estrogenic Effect 103  
 Antigen-presenting cell 3, 14, 15  
 antigen-pulsed 14  
 Anti-hormone resistance cell populations 160  
 Antileukemic immunity 5  
 Anti-oxidant 103, 130  
 enzymes 103  
 signaling pathways 103, 130  
 Anti-proliferative effect of melatonin 120,  
 121, 123, 127, 132  
 Antitumor immunity 5  
 Apoptosis 2, 6, 8, 10, 74, 75, 76, 86, 87, 104,  
 107, 113 120, 121, 128, 129, 133 158,  
 159, 160, 161, 171  
 androgen-induced 160  
 berberine-induced 107  
 cytokine-induced 121  
 effects of hormones 161  
 induction 8, 104, 120  
 melatonin-induced 104  
 pathway 104, 133  
 proteins 113, 128, 171  
 suppressed 161  
 Autoimmune diseases 2, 6

**B**

Brachytherapy 51, 52, 53  
 permanent prostate 52  
 category 53  
 resources 51  
 treatment 51  
 Brain 160, 162, 163, 168  
 hypo-metabolism 160  
 natriuretic peptide 162, 163

- neoplasms 168
  - Brain's DNA repair mechanism 160
  - Breast cancer 14, 85, 99, 156, 160, 173, 175, 178
    - chemotherapy 85
    - development 99, 173, 175, 178
    - therapy 160
    - treatment 14, 156, 178
  - Breast tumors 113, 169, 174
- C**
- Cancer(s) 1, 2, 3, 4, 12, 13, 14, 15, 16, 17, 29, 40, 77, 83, 87, 97, 99, 100, 102, 104, 113, 115, 155, 156, 157, 158, 160, 166, 167, 170, 175, 177, 178
    - breast and prostate 160, 178
    - development 12, 99, 104, 166, 167
    - diagnosis 1, 177
    - female reproductive 157
    - gastric 12
    - gastrointestinal 16
    - gynecologic 170
    - induced mammary 113, 115
    - malignant melanoma 87
    - non-hypermutad 40
    - oesophagal 13
    - pancreas 16
    - prostatic 117
  - Cancer therapy 17, 99, 135, 156, 158, 167, 171, 173, 174
    - anti-thyroid 173
  - Carcinogenesis 83, 123, 126, 129, 130, 135
    - colitis-associated colon 126, 130
    - inhibited colon 129
  - Carcinomas 16, 40, 86, 104, 122, 158, 161, 169
    - hepatocellular 16, 158, 161
    - human breast 169
    - invasive 40
    - ovarian 86, 104
    - prostatic 122
  - Cardiac 11, 155, 156, 162, 163, 164, 165, 166, 167, 177
    - disease 11
    - hormones 155, 156, 162, 163, 164, 165, 166, 167
    - hypertrophy 162
    - rhythmic disorders 177
  - Cardiomyocytes 162
  - Cardiovascular diseases 2, 10, 85
  - Caveolin-mediated endocytosis 2
  - Cell 13, 74, 75, 78, 79, 88, 103, 128, 158, 159
    - apoptosis 78, 158
    - apoptosis mitigated myocardial 79
    - cycle regulation 159
    - damage 103, 128
    - metabolism 75
    - migration 13, 74, 75, 78, 79, 88
  - Cell death 5, 12, 13, 79, 80, 104, 121, 133, 164
    - immune-mediated 5
    - programmed 13, 164
    - promoting myocardial 79
    - triggered nerve 12
  - Central nervous system disorders 7, 9
  - Chemotherapy 99, 107, 110, 117, 130, 131, 133, 134, 135, 155, 156, 158, 159, 171, 172
    - platinum-based 131
  - Chemotherapy's cytotoxic side effects 110
  - Chorionic gonadotropin 159, 161
    - human 161
    - recombinant 159
  - Chronic 6, 12, 86, 87
    - inflammation 6, 12
    - lymphocytic leukemia (CLL) 86, 87
  - Circadian rhythm 97, 98, 120, 122, 123, 135
    - disrupted melatonin 122
  - Cognitive impairment 160
  - Colitis-associated colon carcinogenesis (CACC) 126, 130
  - Collagen homology 75, 77, 78
  - Colonoscopy screening 30
  - Colorectal cancer 30, 42
    - recommendations for serrated polyps 42
    - screening programs 30
  - Conditions 80, 84, 121, 177
    - cardiovascular 177
    - diabetic 84
    - hypoxic 121
    - oxidative 80
  - Congenital ocular melanocytosis GNAQ
    - mutations 48
  - Control 56, 98, 121
    - fuel elements (CFE) 56
    - sympathetic 98
    - untreated 121
  - CpG island methylator phenotype (CIMP) 40
  - Crohn's disease 6

Cryopass-laser treatment 122  
 Cyclin-dependent kinases (CDKs) 104, 133  
 Cytoplasmic proteins 101  
 Cytotoxicity 5, 128, 133, 135, 160  
   cell-mediated 5  
 Cytotoxic 5, 104, 105  
   phenotype 5  
   T lymphocytes (CTLs) 104, 105

**D**

Damage 49, 52, 53, 54, 103, 111  
   cellular 49  
   oxidative 111  
 Dendritic cells 4, 5, 6, 15  
 Dextran sulfate sodium (DSS) 130  
 Diagnosing melanoma 48  
 Diencephalon 97  
 Diseases 1, 4, 6, 9, 12, 16, 50, 54, 74, 97, 99,  
   103, 106, 111, 117, 123, 124  
   bowel 124  
   cancerous 74  
   inherited 48  
   metastatic 50, 54  
   organic 99  
 Disorders 8, 11, 47, 49, 131, 160  
   age-related 160  
   demyelinating 11  
   developing optic nerve 49  
   neurodegenerative 11  
   ovarian 131  
 DNA damage 103, 104, 157, 158, 161  
   prevented 104  
   response (DDR) 157, 158  
 DNA repair 127, 157, 158, 160  
   by regulating essential effector proteins 157  
   capabilities 160  
   effective 158  
   enzymes 160  
 DNA synthesis 127, 128, 166, 167  
   hinder 166, 167  
 DNA vaccines 3  
 Drinking water treatment 130  
 Drug efflux system 7  
 Drugs 85, 113, 128, 130, 178  
   chemotherapeutic 85  
 Dysplasia 29, 32, 37, 38, 39, 40, 41  
   cytological 37, 39  
   serrated 39

**E**

Effect 6, 11, 15, 97, 105, 106, 107, 108, 109,  
   111, 112, 112, 114, 117, 118, 120, 124,  
   128, 129, 131, 135, 161, 164, 166, 167  
   anti-angiogenic 105, 120  
   anti-hypertrophic 164  
   antiproliferative 164, 166, 167  
   cardiac hormone's 166, 167  
   cardiac regenerating 11  
   cytotoxic 107, 128, 135  
   growth factor 161  
   immunomodulatory 15, 107  
   immunosuppressive 6  
   of melatonin 97, 106, 107, 108, 109, 111,  
   112, 113, 114, 117, 118, 120, 124, 129,  
   131  
   on endothelial cells 112  
 Effective treatment methods 106  
 EGFR-recruited signaling 81  
 Endocrine hormone therapy 172  
 Endocrine system 156  
 Endogenous androgens 175, 177  
   circulating 175  
 Endogenous estrogens 175, 177  
   circulating 175, 177  
 Endogenous hormones 155, 156, 175, 176,  
   177, 178  
   and cancer 175  
   management of 155, 156, 175  
 Endometrial cancer 51, 170, 171, 177  
   decreasing 171  
   etiology 177  
   risk 162, 171  
 Endoscopic mucosal resection (EMR) 41  
 Endoscopy 32  
   screening 32  
 Endothelial cells 112, 169  
   human tumor-associated 169  
 Endotheliocytes 162  
 Enzyme guanylate cyclase 166, 167  
 Enzymes 2, 9, 78, 101, 103, 112, 116  
   deactivating aromatase 112  
   developed catalase 9  
 Eosinophilic cytoplasm pencillate nucleus 38  
 Epidermal growth factor receptor (EGFR) 77,  
   134, 173  
 Epididimosomes 2  
 Epigenetic modifications 75  
 Epithelium, adenomatous 30, 40



ER-positive breast cancer cells 172  
 Esophageal squamous cell carcinoma (ESCC)  
 86  
 Estrogen 111, 112, 156, 157, 158, 160, 161,  
 162, 169, 171, 173, 175, 176, 178  
 effect 156  
 hormones 111, 176  
 levels, endogenous 175, 176  
 pathway 103  
 receptor expression 169  
 receptor signaling 157  
 sulfotransferase 112  
 Exosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,  
 13, 14, 15, 16, 17  
 blood-derived 14  
 cancer-derived 4  
 dendritic cells-derived 15  
 immunosuppressive 4  
 inhibiting tumour suppressor 4  
 release 15  
 targeting 15  
 therapeutic 12, 17  
 tumour 5, 15  
 Extracellular secretory vesicles 2  
 Eye 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56,  
 58, 59, 61, 62, 63, 65, 66, 68  
 discharge 54  
 enucleation 46  
 lesions 54  
 plaque brachytherapy 53  
 tumors 46, 50, 52, 54  
 Eye cancer 47, 48, 60  
 treatment 60

**F**

Factors, tumor necrosis 105  
 Fibroblasts 13, 112, 162, 163, 166  
 cancer-associated 13  
 Fibronectin 15  
 Fibrosis 9, 10  
 cystic 9  
 Fluorescent angiography 48  
 Fluoropyrimidine fluorouracil 128  
 Functions 2, 5, 76, 77, 100, 101, 131, 135,  
 155, 157, 158, 164, 173  
 cardiovascular 158  
 cytotoxic 5  
 molecules modulate recipient cell 2

**G**

Gene(s) 75, 83, 85, 101, 104, 105, 107, 112,  
 120, 121, 127, 133, 163, 176  
 anti-apoptosis 104  
 estrogen receptor 112  
 hypoxic 127  
 induced anti-apoptotic 176  
 locus 75  
 murine 112  
 pro-metastatic 83  
 tumor suppressor 112, 133  
 Genetically engineered exosomes (GEEs) 1, 8,  
 9, 17  
 Genetic myopathies 9  
 Genome microarray analysis 121  
 Glutathione 103  
 reduced 103  
 Glycogen, reduced 128  
 Glycolytic metabolisms 88  
 Growth 9, 10, 12, 17, 79, 81, 83, 117, 121,  
 122  
 fibroblast 12  
 factors 9, 10, 17, 79, 81, 83, 117, 121, 122

**H**

Heart 10, 75, 162, 165, 178  
 attack 10  
 Heat shock proteins 2  
 Hematopoiesis 174  
 Hemopoiesis 82  
 Hepatitis 3  
 Hepatocytes 162  
 Homeostasis 2, 87, 164, 156  
 cardiovascular 164  
 cellular 2  
 Hormonal resistance 178  
 Hormone(s) 97, 98, 121, 131, 132, 134, 135,  
 155, 156, 157, 159, 160, 162, 163, 164,  
 165, 166, 167, 168, 171, 173, 174, 175,  
 177, 178  
 cardiac Natriuretic Peptides 162  
 endogenous plasma 177  
 follicle-stimulating 159  
 growth-promoting 166, 167  
 heart 162, 164  
 hormone-releasing 174  
 inactive steroidal 156

ligand 163  
neuropeptide 168  
peptide 162, 164, 165, 166, 167  
pineal 121  
steroid 156, 160, 174  
therapy 173, 175, 177, 178  
Human 10, 105, 108, 112, 114  
  leiomyosarcoma 105  
  telomerase reverses transcriptase 108  
  umbilical vein endothelial cells (HUVECs)  
    10, 112, 114  
Hyperphosphorylation 161  
Hyperplastic polyp (HPs) 29, 30, 31, 32, 33,  
  34, 37, 38  
Hypertension 177  
Hypothalamic-pituitary signaling system 111  
Hypothyroidism 176  
Hypoxia signaling mechanisms 122

**I**

Immune responses 4, 11, 14, 85, 116  
  mediated 85  
Immune 1, 2, 3, 5, 6, 85, 158  
  modulatory agent 6  
  stimulating agents 1  
  suppression 1  
  suppressors 3, 5  
  surveillance 2, 85  
  tolerance 1  
  treatment 158  
Immune system 1, 4, 5, 14, 15, 17, 18, 101,  
  104, 105  
  activating 15  
  adaptive 5  
Immunohistochemistry 29  
Immunostimulatory 168  
Immunosuppressive 4, 6  
  proteins 4  
  roles 6  
Inactivating protein kinase 159  
Inflammatory 6, 12  
  bowel disease 6  
  brain diseases 12  
  diseases, immune-mediated 6  
Injections 119, 122  
  intraperitoneal melatonin 122  
  transdermal 119, 122  
Insulin 101, 171, 175  
  resistance 171

Intercellular 1, 2, 7, 12  
  adhesion molecule 7  
  communications 1, 2, 12  
Intra-tumoral injection of exosomes 8  
Invasion 13, 14, 83, 85, 107, 112, 128, 133,  
  160, 162, 170, 171  
  cellular 83

**K**

Kinases 15, 78, 80, 88, 106, 116, 120, 133,  
  165, 166, 167  
  cyclin-dependent 133  
  extracellular signal-regulated 165  
  extracellular signal-related 166, 167  
  glycogen synthase 116  
  myosin light chain 106  
  transferring receptor tyrosine 15

**L**

Leukaemia 5  
  acute myeloid 5  
  cells 5  
Levels 84, 85, 99, 101, 111, 112, 121, 123,  
  127, 128, 130, 161, 162, 175, 176, 177,  
  178  
  antioxidant enzyme 162  
  deficient 178  
  epigenetic 128  
  estrone 176  
  inflammatory cytokine 12  
Low enriched uranium (LEU) 56  
Lung 13, 87  
  adenocarcinoma 13  
  carcinomas 87  
Lung cancer 74, 81, 97, 106, 108, 109, 110,  
  117, 164, 165, 166, 168, 170, 174  
  human small-cell 165  
  small cell 106, 166  
  squamous cell 164  
Lymphangiogenesis 171  
Lymphatic system 129  
Lymphocytes 4, 5, 7, 15  
Lysosomal 9  
  diseases 9  
  enzyme 9

**M**

- Macrophages 9, 12, 15, 104, 162
  - Macropinocytosis 2
  - Magnetic nanocomposite particles (MNPs) 113
  - Malignancies 156, 166
    - hematologic 166
    - progress breast 156
  - Malignant pericardial effusion 166
  - Mammary gland malignancy development 161
  - Mammary tumor 113, 116
    - developed 116
    - developing 113
  - Management, effective therapy 156
  - Maturation, effective 5
  - Mechanisms 158, 163
    - proteolytic 163
    - suppressive 158
  - Melanocytes 47
  - Melanoma 15, 17, 47, 48, 52, 53, 54, 147, 158
    - cancer cells 15
    - cutaneous 47
    - iris 47
  - Melanoma cells 87
    - exosomes 15
    - inhibitory activity protein 87
  - Melatonin 98, 100, 101, 105, 110, 111, 117, 120, 123, 127
    - hormone 100, 101
    - membrane receptors 117, 120, 127
    - pathways 123
    - promises 111
    - secretion 98
    - serum levels 110
    - therapy 105
  - Menopause 157, 158, 160
  - Metabolic syndrome 171
  - Metabolism 74, 88, 110, 116, 121, 161, 168
    - anabolic 88
  - Metachromatic leukodystrophy 9
  - Metalloproteinase 170
  - Metastasis 12, 15, 17, 48, 55, 82, 83, 84, 87, 88, 106, 107, 109, 110, 173, 183
    - breast cancer lung 83
    - regulating tumor cell 83
    - small 55
    - suppress breast cancer 173
  - Methods 83, 101, 174
    - castration 174
    - protein-related 83
    - receptor-independent 101
  - MicroRNAs 11, 16, 121, 173
    - exosomal 16
  - Microvesicular HPs (MVHPs) 31, 33, 34, 35, 40, 41
  - Migration 13, 14
    - of breast cancer cells 13
    - of osteosarcoma cells 14
  - Mitogen-activated protein 13, 74, 77, 80, 104, 134, 169
    - kinases (MAPK) 13, 74, 77, 80, 104, 134
  - Mitogenic signals, transducing 88
  - Morphology, macroscopic 37
  - Mortality rates 117, 123, 130
  - Mutated mismatch repair (MMR) 41
  - Mutations 8, 9, 40, 47, 85, 107
    - single gene 9
    - somatic 107
  - MWth pool-type reactor 56
  - Myocardial 10, 11, 17
    - infarction 10, 11, 17
    - necrosis 10
- N**
- Natriuresis 162
  - Natriuretic peptides 162, 165, 166, 167
  - Natural 104, 161
    - cancer-protective agents 161
    - killer (NK) 104
  - Neoplasia pathway 40
  - Neoplastic Cells 168
  - Neuroblastoma 13
  - Neurodegenerative diseases 2, 12
  - Neuronal cell adhesion molecule (NCAM) 82
  - Neurons 98
    - postganglionic 98
    - sympathetic 98
  - Neutrophils 162
  - Nitrotyrosine 84
  - Non-canonical hedgehog 174
  - Non-small cell lung cancer (NSCLC) 5, 13, 106, 107, 110
  - Norepinephrine 98
  - Nuclear protein 122
  - Nucleic acids 8, 9, 11, 16, 17
    - therapeutic 8
  - Nucleus 78, 80, 98, 101, 128, 166, 167, 168
    - of cancer cell 167

suprachiasmatic 98  
supraoptic 168  
tractus solitaries 168

**O**

Obese-dependent cardiotoxicity 177  
Oophorectomy 175  
Organs 53, 87, 105  
  immune 105  
  peripheral lymphoid 87  
  respiratory 53  
Osteoporosis 156  
Ovarian cancer 83, 86, 97, 100, 130, 131, 133,  
  134, 135, 170, 177  
  cell proliferation 86  
  developing 135  
  induced 133  
  pathophysiology 170  
Oxaliplatin-resistant colorectal cancer 125  
Oxidative stress 74, 78, 79, 80, 81, 84, 85, 87,  
  103, 110, 135, 174  
  regulation 85  
  stimuli 81  
  stimulus 80  
Oxytocin 155, 156, 168, 169, 170, 171  
  neurohypophyseal hormone 168  
  and brain cancer 169  
  and breast cancer 169  
  and endometrial cancer 170  
  and lung cancer 170  
  and prostate cancer 171  
  effects 169, 170  
  hormones 155, 156, 168  
  treatment 170  
Oxytocinergic system 168, 170  
  in neoplastic cells 168  
Oxytocin receptor 168, 169, 170, 171  
  signaling 169

**P**

Pancreatic adenocarcinoma cells 164, 165  
  166, 167  
  human 165, 166, 167  
Pancreatic cancer 1, 17, 75  
Pathogenesis 30, 47, 48, 116, 117, 124  
  colorectal carcinoma 30  
Pathologic features of serrated lesions 32

Pathways 2, 3, 13, 30, 40, 74, 75, 80, 81, 82,  
  84, 98, 121, 128, 134, 160, 176  
  activating Raf/MAPK 82  
  apoptotic 74  
  block cell survival 160  
  endocytic 2  
  endosomal 3  
  epithelial-mesenchymal transition 128  
  mediated apoptotic 81  
  mediated Ras/MAP Kinase 81  
  metabolic 134  
  mTOR signalling 13  
  pentose phosphate 121  
  retino-hypothalamic 98  
  serrated neoplastic 30  
  signal transduction 75  
  stress-associated 134  
Phagocytosis 2, 7, 8  
Phenotype 4, 6, 17, 82, 83  
  aggressive 17  
  immunosuppressive 4  
  metastatic 82, 83  
Phenotypical stability 6  
Phosphotyrosine interaction domain (PID) 76  
Photons 53, 55  
  low-energy 55  
  radiant 53  
Physiological 88, 98, 112, 155, 156, 157, 175  
  diurnal variation 112  
  functions 88, 98, 155, 156, 157, 175  
Plaque 46, 47, 50, 51, 52, 53, 54, 55, 56, 57,  
  58, 59, 60, 61, 62, 63, 64, 66, 67, 68  
  based brachytherapy 53  
  brachytherapy 46, 50, 52, 54  
  in eye and tumor 46, 61, 62, 63, 66  
  shield of 58, 59  
  treatments 51  
Pleckstrin homology (PH) 76  
Polycystronic ovary syndrome 84  
Premenopausal testosterone 176  
Preneoplastic changes 129  
Progesterone receptors 159, 157, 161, 171,  
  173, 175  
  estrogen expression 159  
Progesterone treatment 161  
Prognosis 1, 29, 83, 134  
Progression 2, 4, 12, 17, 74, 75, 85, 86, 87, 88,  
  158, 165, 173  
  hepatocellular carcinoma 173  
  pathological 2

- tumour 4
  - Proliferative prostate disease 159
  - Prostate cancer 86, 117, 123, 159
    - adenocarcinomas 86
    - development 159
    - incidence of 117
    - metastatic 123
    - risk 123, 177
  - Prostate-specific antigen (PSA) 123
  - Proteases 104
  - Protein kinase 13, 74, 80, 104, 120, 122, 128, 134, 159, 164, 166, 167
    - activating mitogen-activated 74
    - mitogen-activated 13, 80, 104, 134, 166, 167
    - signaling pathway 128
  - Protein tyrosine phosphatases 82
- R**
- Radiation 49, 51, 53, 55, 58, 103, 128, 135, 155, 156
    - infrared 49
  - Radiation 48, 49, 50, 51, 109, 171, 173, 174
    - injury 174
    - therapy 48, 49, 50, 51, 109, 171, 173, 174
    - therapy methods for melanoma treatment 50
  - Radioactive elements 56
    - in reactors 56
    - production 56
  - Radioisotope production 56, 64
  - Radionuclide therapy 55
  - Radiotherapy 46, 50, 51
    - systemic 50
    - methods 46
    - operation 51
  - Reactive 74, 75, 78, 103, 127, 128, 130, 131, 159
    - nitrogen species (RNS) 103
    - oxygen species (ROS) 74, 75, 78, 103, 127, 128, 130, 131, 159
  - Receptors 80, 81, 84, 87, 101, 120, 121, 128, 134, 156, 159, 163, 166, 167, 171, 173
    - activating VEGF 84
    - androgen 121, 159
    - cell surface 166, 167
    - chemokine 87
    - epidermal growth factor 134, 173
    - estrogen alpha 156
    - inositol triphosphate 128
    - membrane MT1a 120
    - protein-coupled 171
    - retinoid orphan 101
    - transmembrane 84, 163
    - tyrosine kinase 81
    - tyrosine-kinase 80
  - Regulating essential effector proteins 157
  - Renal filtration 7
  - Resistance 158, 160
    - anti-hormone 160
    - treating-drugs reverses chemotherapy 158
  - Reticuloendothelial system 8
  - Retinal 49
    - hole 49
    - neovascularization 49
  - Retinoid Z receptor (RZR) 101
  - Rheumatoid arthritis 6
  - Rho 83, 113
    - associated protein kinase 113
    - family proteins and ERK proteins 83
  - Ribosomal protein 120
  - RKO colon cancer cells 128
  - RNA 11, 75, 163
    - expression 163
    - molecules 11
    - splicing 75
  - RNAs 11, 13
    - competing endogenous 13
    - non-coding 11
  - Role 74, 75, 81, 84, 85, 98, 99, 100, 104, 105, 107, 110, 124, 132, 156, 164, 168, 170, 173, 174, 178
    - effective 107
    - multifunctional 81
    - of cancer stem cells 173
    - oncostatic 132
    - oxytocin's 170
    - radio-protective 110
  - ROS 78, 79, 80, 84, 85, 130
    - by transferring electrons 79
    - oncogenic 130
    - oncosuppressive 130
    - overproduction of 84, 85
    - scavenging enzymes 78, 80
  - ROS production 84
    - and apoptosis of marginal cells 84
    - enhancing 84

**S**

Serrated adenomas (SAs) 30, 36, 41  
 Serum 9, 17, 98  
   melatonin level 98  
   proteins 9, 17  
 Sessile serrated lesion (SSLs) 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41  
 Sex hormones 156, 177  
   endogenous 177  
   in anti-cancer management 156  
 Sex hormones 157, 160  
   influence 157  
   variations 160  
 Signaling pathways 48, 80, 104, 105, 157, 159, 163, 169, 172, 178  
   downstream 163  
   intracellular 159  
   regulated 80  
 Signal transducer and activator of transcription 167  
 SiRNA 1, 8, 82  
   approach 82  
   therapeutic 1  
 Small cell lung cancer (SCLC) 5, 13, 106, 166  
 Squamous cell carcinoma 16, 106, 166  
   invasion 166  
 Standard fuel elements (SFE) 56  
 Stem cells 6, 8, 10, 12, 13, 14, 173, 174, 178  
   adipose tissue-derived mesenchymal 8  
   breast mammary 178  
   human adipose-derived mesenchymal 13  
   inhibiting cancer 174  
   menstrual 12  
   mesenchymal 6, 10, 12, 14, 174  
   papillary thyroid cancer 173  
   residual cancer 173  
   thyroid 173  
 Stemness-related factors expression 173  
 Stereotactic radiosurgery 50, 51  
 Steroid treatment of ovarian cancer 86  
 Stratification 39  
*Streptococcus pneumoniae* 3  
 Stress 168  
 Surgical pinealectomy 115  
 Sympathetic 98, 164  
   fibers 98  
   nervous system 164  
 Synaptic contact 98  
 Synthesis 10, 78, 100, 112, 128, 163, 172, 176

collagen 10  
 Synthesis of estrogens 176

**T**

Techniques 49, 51, 54, 55  
   external beam radiotherapy 54  
   intra-chip 51  
 Tecplot software 65  
 Therapy 15, 16, 152, 156, 158, 159, 172, 178  
   cancer disease 158  
   endocrine 157, 172, 178  
   hormone deprivation 158  
   hormone replacement 159  
   immune combination 158  
 Thermotherapy 49  
   transpupillary 49  
 Thrombocytopenia 123  
 Thyroid 74, 82, 87, 173, 176  
   cancers 74, 82, 87, 173  
   hormones 176  
 Traditional serrated adenoma (TSAs) 29, 31, 32, 34, 37, 38, 39, 41, 42  
 Transcription 76, 101, 103, 105, 112, 167  
   factors 101  
 Transcriptomic analysis 85  
 Transformation 40, 82, 161  
   neoplastic 40, 161  
 Transition 84, 107, 133  
   epithelialmesenchymal 107  
   epithelial-mesenchymal 133  
 Translocation 78, 80, 121, 128  
   nuclear 121  
 Transmit infections 3  
 Tricarboxylic acid cycle 121  
 Tryptophan 78, 100, 110  
   essential amino acid 100  
 Tubular adenoma 32, 41  
   containing sporadic 41  
 Tumor 83, 109, 157, 160, 168, 172  
   growth stimulation 160  
   gynecologic 168  
   hormone-dependent 157  
   metastasis 83  
   treatments 172  
   xenograft 109  
 Tumor cells 101, 104, 111, 112, 113, 128, 129, 130, 133, 134, 165, 166, 167, 172, 177  
   affected 104

brain 172  
estrogen-responsive breast 112  
fighting 129  
growth of 104, 130  
malignant 177  
Tumor growth 84, 121, 164, 169, 170, 173  
modulate 170  
promoting 84  
Tumor suppressor 112, 161  
protein 112, 161  
Tumorigenesis 74, 172  
Twist signaling pathway 107

## U

UMs harbor mutations 48  
Upstream GTPase 165  
Utility, prognostic 17

## V

Vaccination 5, 17  
Vaccines 3, 4, 5  
development 3, 5  
exosome-based 3  
production 4  
tumour 4  
Vascular endothelial growth factor (VEGF)  
13, 84, 105, 106, 112, 120, 127, 134,  
166, 167  
Viral 3  
diseases 3  
infections 3  
proteins, expressing 3  
Vision 48, 49, 50, 52, 54  
loss 48  
Visual impairment 111

## W

Waste disposal mechanism 2  
Women 135, 159, 160, 171, 173, 175, 176,  
177  
healthy 135  
menopausal 160  
menstruated 176  
obese 171  
postmenopausal 159, 173, 175, 177  
premenopausal 171, 175


World health organization (WHO) 29  
Wound healing 10  
aid 10

## X

Xenografts 119, 122  
Xenon laser photocoagulation 49  
X-linked inhibitor 171

## Z

Zenoid melanoma choroidal fructocoagulation  
49



**PROF. DR. ATTA-UR-RAHMAN, FRS**

---

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.